"In the Phase 1 trail CKD in New Zealand, can the results of that trial indicate to management what might be happening with the patients in BETonMACE CKD sub-group patients,...? Is it possible they will see indications that Apabetalone is working as hoped for in thta sub-group,...?"

Cabel, you are referring to this trial and this publication. This trial assessed plasma proteome changes (via SOMAscan SomaLogic technology) in healthy vs. stage 4/5 CKD patients at baseline and also treated for 24-48 hours with apabetalone. BETonMACE CKD patients are limited to stage 3. However, it is VERY likely that many of the same proteins found to be significantly elevated or reduced in the Stage 4/5 patients are also similarly elevated or reduced in the Stage 3 patients. It is also VERY likely that apabetalone will effect the protein expression similarly in Stage 3 patients as it did in Stage 4/5 patients. 

Now, has Resverlogix proceeded with any SomaScan analysis of BETonMACE blinded samples? I have no idea.

BearDownAZ